Addex Therapeutics announced the appointment of Jean-Philippe Rocher, PhD, as Co-Head of Discovery and Member of the Executive Management, effective 1 June 2018. Together with Robert Lütjens, Addex's current Head of Discovery, he will oversee the preclinical portfolio of proprietary allosteric modulator programs and lead the chemistry components of funded research programs on GABAB PAM with Indivior PLC and TrkB PAM with the Michael J. Fox Foundation for Parkinson's Research. Dr. Rocher returns to Addex from his current position as CNS Program Director at Pierre Fabre. Joining Addex at its inception in 2002, Dr. Rocher established the company's chemistry capabilities and helped build its small molecule allosteric modulator chemistry platform and pipeline.